Gloria D. L. R. B.
- Country
- Spain
- Department
- Internal Medicine
Research Overview
- Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of Long-term Safety and Tolerability of Dazodalibep in Patients with Sjögren’s Syndrome: A Multicenter, Randomized Extension Study
Data & Insights
Has run more than one trial at 79 of 106 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in studying Sjögren's Syndrome, with particular emphasis on cases involving moderate-to-severe systemic disease activity.
- Primary Sjögren's Syndrome Management
- Systemic Disease Manifestations
- Novel Therapeutic Approaches
The research focus encompasses comprehensive evaluation of therapeutic interventions for patients with systemic manifestations of autoimmune conditions.
Clinical Safety Assessment
The investigator conducts extensive research in long-term safety evaluation of innovative therapeutic agents for autoimmune conditions.
- Treatment Tolerability Studies
- Safety Monitoring Protocols
- Long-term Patient Outcomes
Their work involves detailed assessment of therapeutic tolerability in patients with complex autoimmune manifestations.
Therapeutic Innovation
Research activities center on evaluating novel treatment approaches for autoimmune disorders, particularly in addressing systemic complications.
- Treatment Efficacy Assessment
- Disease Activity Monitoring
- Therapeutic Response Evaluation
The investigator's work focuses on developing effective interventions for managing complex autoimmune conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.